The IV drip that treats a deficiency and adds exacerbations
Cochrane found intravenous AAT therapy raised yearly exacerbations to 1,960 per 1,000 people, versus 1,420 on placebo.
By The Weekend · · 5 min read
A treatment meant to protect the lungs of people with a rare genetic deficiency may be making one of the things it's supposed to prevent slightly more common. A Cochrane review of six trials found that people receiving intravenous alpha-1 antitrypsin augmentation therapy experienced 1,960 exacerbations per 1,000 people per year, compared with 1,420 per 1,000 on placebo — 290 more flare-ups, not fewer.
524 patients, six trials, one uncomfortable number
Alpha-1 antitrypsin deficiency (AATD) is a genetic condition in which the body fails to produce enough of a protein that shields lung tissue from damage caused by the body's own enzymes. Left unchecked, it can progress to chronic obstructive pulmonary disease, and smokers with the deficiency face a sharply elevated risk of severe lung disease. Augmentation therapy tries to correct the shortfall by infusing donor-derived AAT protein back into patients — through a vein, under the skin, or inhaled via a breathing mask.
The Cochrane review, funded through Cochrane's standard editorial process rather than by a drug manufacturer, pooled six randomized trials covering 524 participants across Europe, North America and Australia. Four trials tested the intravenous route; two tested inhaled delivery. All were placebo-controlled. The smallest trial had five participants; the largest had 180. That is the entire evidence base for a therapy that has been in clinical use for decades.
The headline result inverts the expectation: intravenous augmentation therapy showed a rate of 1,960 exacerbations per 1,000 patient-years, against 1,420 per 1,000 on placebo. In practical terms, a patient on the infusion experienced roughly 38% more exacerbation events over a year than one taking a dummy treatment. That is not a rounding artifact — it is the direction opposite to what the therapy is designed to do.
Why 524 patients is both the whole story and not enough of one
The number sounds larger than it is, and smaller than it should be, depending on which way you look. It sounds large because it's a real, measured difference across randomized trials — the kind of data structure that normally earns confidence. But 524 people split across six separate studies, with individual trial sizes ranging from five to 180, is a thin foundation for any firm conclusion about a chronic, slow-moving lung disease. Cochrane's own verdict is blunt: reviewers say they have "little confidence in the evidence" precisely because there are so few studies and so few participants in each.
There's also a measurement problem baked into exacerbation counting itself. Exacerbations are self-reported or clinician-assessed worsening events, not a lab value with a fixed threshold — different trials may have used different diagnostic thresholds for what counts as an exacerbation, which can inflate or dampen the apparent difference between groups. A rate difference this size, drawn from a pooled sample this small, could plausibly shrink, vanish or reverse with a single additional large trial.
What the review does not find, meanwhile, matters just as much as what it does. Intravenous augmentation therapy showed little or no effect on mortality — patients were not more likely to die on the treatment than on placebo. And reviewers say they simply don't know whether the therapy changes rates of serious adverse events like hospitalization or permanent organ damage, because the trials weren't equipped to answer that question with confidence.
The counter-argument: absence of harm to the lungs' actual job
The strongest case for augmentation therapy was never that it eliminates exacerbations — it's that the protein is doing its intended structural job of slowing lung tissue breakdown, a process that shows up on imaging and lung-function tests over years, not in an annual exacerbation tally. Advocates for the therapy have long pointed to observational data suggesting it slows the loss of lung density measured by CT densitometry, a slower and quieter outcome than a flare-up count. If augmentation therapy is protecting tissue architecture even while exacerbation counts creep up, then judging the treatment purely on exacerbation rate risks throwing out a real long-term benefit because it doesn't show up in the metric being tracked.
That argument is not addressed by this review, because none of the six included trials measured lung densitometry with enough consistency to pool. It's a real gap, and it means the exacerbation number, however carefully counted, isn't the whole clinical picture — it's the one part of the picture that happened to be measured well enough to compare.
The inhaled route offers a mirror image of uncertainty. Two small trials tested breathing-mask delivery, and reviewers say they don't know whether it affects exacerbation rates at all — the evidence simply isn't there. Inhaled therapy showed little or no difference in serious adverse events compared with placebo, which sounds reassuring, but with so few participants tested, "little or no difference" is closer to "no detectable signal either way" than "safe."
What happens to a therapy already prescribed for decades
Augmentation therapy is not a new or experimental treatment — it has been used clinically since the late 1980s, and treatment guidelines in multiple countries already recommend it for patients with confirmed severe deficiency and evidence of lung disease. This review doesn't overturn those guidelines outright, because it doesn't show the therapy is unsafe or lethal. What it does is remove the assumption that augmentation therapy straightforwardly reduces the day-to-day burden of exacerbations, which is one of the outcomes patients actually feel and one that clinicians commonly cite when recommending the treatment.
The practical next step is not a ban but a larger trial — one big enough to settle whether the 290-exacerbation gap is real, whether it's an artifact of small samples, and whether it's outweighed by slower structural lung damage that this review wasn't built to detect. Until that trial exists, patients and clinicians are choosing a therapy on the strength of six small studies, a genetic diagnosis that already narrows the population to a fraction of COPD patients, and a number — 1,960 versus 1,420 — that cuts against the story the treatment has told about itself for thirty years.